Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State

Show full item record



Permalink

http://hdl.handle.net/10138/306354

Citation

Tikkanen , E , Minicocci , I , Hällfors , J , Di Costanzo , A , D'Erasmo , L , Poggiogalle , E , Donini , L M , Wurtz , P , Jauhiainen , M , Olkkonen , V M & Arca , M 2019 , ' Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State ' , Arteriosclerosis, Thrombosis, and Vascular Biology , vol. 39 , no. 4 , pp. 665-674 . https://doi.org/10.1161/ATVBAHA.118.312021

Title: Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State
Author: Tikkanen, Emmi; Minicocci, Ilenia; Hällfors, Jenni; Di Costanzo, Alessia; D'Erasmo, Laura; Poggiogalle, Eleonora; Donini, Lorenzo Maria; Wurtz, Peter; Jauhiainen, Matti; Olkkonen, Vesa M.; Arca, Marcello
Contributor: University of Helsinki, Medicum
Date: 2019-04
Language: eng
Number of pages: 10
Belongs to series: Arteriosclerosis, Thrombosis, and Vascular Biology
ISSN: 1079-5642
URI: http://hdl.handle.net/10138/306354
Abstract: Objective- Loss-of-function (LOF) variants in the ANGPTL3 (angiopoietin-like protein 3) have been associated with low levels of plasma lipoproteins and decreased coronary artery disease risk. We aimed to determine detailed metabolic effects of genetically induced ANGPTL3 deficiency in fasting and postprandial state. Approach and Results- We studied individuals carrying S17X LOF mutation in ANGPTL3 (6 homozygous and 32 heterozygous carriers) and 38 noncarriers. Nuclear magnetic resonance metabolomics was used to quantify 225 circulating metabolic measures. We compared metabolic differences between LOF carriers and noncarriers in fasting state and after a high-fat meal. In fasting, ANGPTL3 deficiency was characterized by similar extent of reductions in LDL (low-density lipoprotein) cholesterol (0.74 SD units lower concentration per LOF allele [95% CI, 0.42-1.06]) as observed for many TRL (triglyceride-rich lipoprotein) measures, including VLDL (very-low-density lipoprotein) cholesterol (0.75 [95% CI, 0.45-1.05]). Within most lipoprotein subclasses, absolute levels of cholesterol were decreased more than triglycerides, resulting in the relative proportion of cholesterol being reduced within TRLs and their remnants. Further, beta-hydroxybutyrate was elevated (0.55 [95% CI, 0.21-0.89]). Homozygous ANGPTL3 LOF carriers showed essentially no postprandial increase in TRLs and fatty acids, without evidence for adverse compensatory metabolic effects. Conclusions- In addition to overall triglyceride- and LDL cholesterol-lowering effects, ANGPTL3 deficiency results in reduction of cholesterol proportion within TRLs and their remnants. Further, ANGPTL3 LOF carriers had elevated ketone body production, suggesting enhanced hepatic fatty acid beta-oxidation. The detailed metabolic profile in human knockouts of ANGPTL3 reinforces inactivation of ANGPTL3 as a promising therapeutic target for decreasing cardiovascular risk.
Subject: biomarkers
fasting
humans
lipoproteins
metabolomics
FAMILIAL COMBINED HYPOLIPIDEMIA
GENETIC INHIBITION
ANGPTL3 GENE
MUTATIONS
RISK
TRIGLYCERIDES
EPIDEMIOLOGY
LIPOPROTEINS
LIPIDS
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
ATVBAHA.118.312021.pdf 1.209Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record